ASRT Long Call Strategy

ASRT (Assertio Holdings, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

ASRT (Assertio Holdings, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $150.7M, a beta of 0.45 versus the broader market, a 52-week range of 8.61-23.36, average daily share volume of 227K, a public-listing history dating back to 1997, approximately 58 full-time employees. These structural characteristics shape how ASRT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.45 indicates ASRT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on ASRT?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current ASRT snapshot

As of May 15, 2026, spot at $23.34, ATM IV 113.80%, IV rank 19.65%, expected move 32.63%. The long call on ASRT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on ASRT specifically: ASRT IV at 113.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a ASRT long call, with a market-implied 1-standard-deviation move of approximately 32.63% (roughly $7.61 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ASRT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ASRT should anchor to the underlying notional of $23.34 per share and to the trader's directional view on ASRT stock.

ASRT long call setup

The ASRT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ASRT near $23.34, the first option leg uses a $23.34 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ASRT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ASRT shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$23.34N/A

ASRT long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ASRT long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ASRT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ASRT

Long calls on ASRT express a bullish thesis with defined risk; traders use them ahead of ASRT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ASRT thesis for this long call

The market-implied 1-standard-deviation range for ASRT extends from approximately $15.73 on the downside to $30.95 on the upside. A ASRT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ASRT IV rank near 19.65% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ASRT at 113.80%. As a Healthcare name, ASRT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ASRT-specific events.

ASRT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ASRT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ASRT alongside the broader basket even when ASRT-specific fundamentals are unchanged. Long-premium structures like a long call on ASRT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ASRT chain quotes before placing a trade.

Frequently asked questions

What is a long call on ASRT?
A long call on ASRT is the long call strategy applied to ASRT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ASRT stock trading near $23.34, the strikes shown on this page are snapped to the nearest listed ASRT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ASRT long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ASRT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 113.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ASRT long call?
The breakeven for the ASRT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ASRT market-implied 1-standard-deviation expected move is approximately 32.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ASRT?
Long calls on ASRT express a bullish thesis with defined risk; traders use them ahead of ASRT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ASRT implied volatility affect this long call?
ASRT ATM IV is at 113.80% with IV rank near 19.65%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ASRT analysis